6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands

US11390623B2 · kind B2 · utility

Assignee

• PFIZER INC. · US

Inventors

• Thomas Allen Chappie · Old Lyme, US
• Jaclyn Louise Henderson · Cambridge, US
• Joseph Michael Young · Madison, US
• Travis T. Wager · Brookline, US
• Bethany Lyn Kormos · Somerville, US
• Nandini Chaturbhai Patel · Newton, US
• Simone Sciabola · Cambridge, US
• Jamison Bryce Tuttle · Pasadena, US
• Patrick Robert Verhoest · Newton, US
• Joseph Walter Tucker · New London, US

Key dates

• Filing date: Jan 23, 2020
• Grant date: Jul 19, 2022
• Expiry date: Jan 23, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/36
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.